OPTEL GROUP, a leading global provider of traceability systems for the pharmaceutical, medical device, and healthcare industries, announced today that it has signed an agreement to pilot OPTEL’s Certa decommissioning solution at Oxford University Hospitals (OUH) to enable the world-renowned institution to comply with the European Union’s Falsified Medicines Directive (FMD).
OPTEL GROUP, a leading global provider of traceability systems for the pharmaceutical and medical device industries, announced that it has extended its expertise to include solutions for the healthcare industry, namely for hospital and retail pharmacies.
For more information, please consult our Latest News section below.
Verifying the status of healthcare products with the NMVS ─ providing unfailing and instantaneous notification of any non-conformities.
Deactivating product identifiers once medication is dispensed – ensuring patient safety through data status modification.
Reactivating product identifiers on time – helping create a more sustainable healthcare system by reducing waste and increasing overall patient care.